Analyst Price Targets — IOVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 12:53 pm | Andrea Newkirk | Goldman Sachs | $2.00 | $2.44 | TheFly | Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs |
| May 16, 2025 8:43 am | David Dai | UBS | $2.00 | $1.66 | TheFly | Iovance Biotherapeutics downgraded to Neutral from Buy at UBS |
| February 28, 2025 11:49 am | — | Piper Sandler | $6.00 | $4.24 | TheFly | Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler |
| January 31, 2025 11:40 am | Joseph Catanzaro | Piper Sandler | $7.50 | $5.85 | TheFly | Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler |
| October 24, 2024 3:53 am | David Dai | UBS | $17.00 | $9.82 | StreetInsider | UBS Starts Iovanace Biotherapeutics (IOVA) at Buy |
| August 9, 2024 7:56 am | Benjamin Burnett | Stifel Nicolaus | $11.50 | $3.97 | StreetInsider | Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel |
| August 9, 2024 6:35 am | Colleen Kusy | Robert W. Baird | $12.00 | $3.97 | StreetInsider | Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird |
| July 29, 2024 2:11 am | Joseph Catanzaro | Piper Sandler | $10.00 | $9.25 | StreetInsider | Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral |
| June 20, 2024 6:20 am | Reni Benjamin | JMP Securities | $11.50 | $4.00 | TheFly | Iovance Biotherapeutics price target lowered to $23 from $25 at JMP Securities |
| May 31, 2024 3:08 pm | Benjamin Burnett | Stifel Nicolaus | $14.00 | $4.44 | StreetInsider | Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA) |
Latest News for IOVA
SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options…
Iovance Biotherapeutics' most important product is generating rapidly growing sales. Between approvals in other countries and label expansions, it could maintain its momentum for a while.
Aberdeen Group plc raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) by 25.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 759,522 shares of the biotechnology company's stock after buying an additional 152,312 shares during
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report)'s share price passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.42 and traded as low as $3.28. Iovance Biotherapeutics shares last traded at $3.30, with a volume of 9,777,900 shares traded. Wall Street Analyst Weigh In
Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73% disease control, outperforming pivotal trial results and driving increased physician adoption in less heavily pretreated patients. IOVA's pipeline catalysts include pivotal NSCLC data in 2024, sarcoma expansion with…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IOVA.
U.S. House Trading
No House trades found for IOVA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.